『Modern Clinical Management of Thyroid Carcinoma and the Hospitalist's Role in Coordination』のカバーアート

Modern Clinical Management of Thyroid Carcinoma and the Hospitalist's Role in Coordination

Modern Clinical Management of Thyroid Carcinoma and the Hospitalist's Role in Coordination

無料で聴く

ポッドキャストの詳細を見る
In this episode of Hospital Medicine Unplugged, we sprint through thyroid cancer—understand the epidemiologic paradox of rising incidence but stable mortality, stage disease using modern AJCC criteria, apply ATA recurrence risk stratification, and tailor therapy from surgery and radioiodine to targeted molecular treatments. We start with the epidemiology of thyroid carcinoma, the most common endocrine malignancy and the ninth most common cancer worldwide. In 2022 alone, there were roughly 821,000 new cases and 47,500 deaths globally. The disease shows a strong female predominance—about three quarters of cases occur in women, and the median age at diagnosis is in the early 50s. Notably, thyroid cancer is also the most common malignancy among adolescents and young adults aged 16–33 years. One of the most striking trends is the dramatic rise in incidence over the past four decades. Global age-standardized incidence increased substantially from about 2.1 per 100,000 in 1990 to over 3.1 per 100,000 in 2017, with extremely high rates reported in countries such as South Korea, Cyprus, Ecuador, China, and Turkey. Yet mortality has remained remarkably stable at roughly 0.5 per 100,000, suggesting that much of the increase reflects overdiagnosis rather than a true surge in aggressive disease. The driver behind this phenomenon is increased detection of small papillary thyroid cancers, often discovered incidentally during thyroid ultrasonography or cross-sectional imaging. Some studies estimate that more than 75% of thyroid cancers globally may represent overdiagnosis, particularly in high-income countries where imaging is widespread. Encouragingly, incidence rates have begun to plateau or decline in some regions following guideline changes discouraging unnecessary biopsy and treatment of very small nodules. Next, we turn to staging, which guides prognosis and management. The AJCC 8th edition TNM staging system introduced an important shift by raising the prognostic age cutoff from 45 to 55 years. This reflects the excellent survival outcomes seen in younger patients. For patients younger than 55 years, staging is remarkably simple: • Stage I: any tumor size, any lymph node status, no distant metastasis • Stage II: distant metastasis present This simplified system reflects the outstanding prognosis in younger individuals, with more than 98% survival regardless of tumor characteristics. For patients 55 years and older, staging becomes more detailed and incorporates tumor size, lymph node involvement, and extrathyroidal extension. Importantly, the 8th edition refined the definition of extrathyroidal extension so that only gross invasion of strap muscles qualifies for T3b staging, which has downstaged many patients and improved prognostic accuracy. However, staging alone does not fully predict recurrence. That role belongs to the American Thyroid Association (ATA) risk stratification system, which categorizes patients as low, intermediate, or high risk of recurrence. Approximate recurrence rates are: • Low risk: ~1.5% • Intermediate risk: ~5% overall • High risk: ~25% A key innovation in ATA management is dynamic risk stratification, where risk is continuously updated based on response to therapy. Response categories include: • Excellent response: ~4.7% recurrence risk • Indeterminate response: ~17% recurrence • Biochemically incomplete: ~58% recurrence • Structurally incomplete: ~84% recurrence This dynamic approach allows clinicians to de-escalate surveillance and treatment for patients who demonstrate excellent responses over time. At the molecular level, thyroid cancer has a remarkably simple genomic landscape, dominated by mutations activating the MAPK signaling pathway. The most common driver mutation is BRAF V600E, found in about 60% of papillary thyroid cancers. This mutation is associated with classic and tall-cell variants, increased lymph node metastases, and reduced responsiveness to radioactive iodine due to suppression of the sodium-iodide symporter. Another important group includes RAS mutations, seen in follicular thyroid cancers and follicular-variant papillary carcinomas. These tumors often demonstrate vascular invasion but retain better responsiveness to radioactive iodine therapy. Chromosomal rearrangements also play a role. RET/PTC fusions are common in radiation-induced thyroid cancers and pediatric cases, while TERT promoter mutations—particularly when combined with BRAF mutations—are associated with aggressive disease and poor prognosis. Management of differentiated thyroid cancer increasingly emphasizes risk-adapted therapy, particularly regarding radioactive iodine (RAI). RAI can serve three purposes: • Remnant ablation after surgery • Adjuvant therapy to reduce recurrence risk • Treatment of known metastatic disease Modern guidelines recommend avoiding routine RAI in low-risk patients, particularly those with small intrathyroidal papillary cancers ≤2 cm, ...
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません